LBA1 Ceralasertib (C) + durvalumab (D) in patients (pts) with locally advanced (LA) or metastatic (m) NSCLC who progressed on or after anti-PD-(L)1 and platinum-based chemotherapy (CT): Results from LATIFY
Year: 2026
Type: article
Study design: Clinical Trial
Abstract: Pts with advanced NSCLC and disease progression on or after anti-PD-(L)1 ± platinum-based CT (concurrent or sequential) have limited treatment (tx) options. The phase 3, randomized, open-label, multicentre LATIFY study (NCT05450692) evaluated C (a selective inhibitor of the ATR DNA damage response kinase) + D (anti-PD-L1) vs docetaxel in pts with LA/mNSCLC, without actionable genomic alterations, after progression on or after anti-PD-(L)1 and platinum-based CT. We report results of the primary and final analysis.
Source: ESMO Open
Institutions: Institut Gustave Roussy, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Yonsei University, Yonsei Cancer Hospital, Shizuoka Cancer Center, Yale Cancer Center, Chinese Academy of Medical Sciences & Peking Union Medical College, Cancer Hospital of Chinese Academy of Medical Sciences, Instituto do Câncer do Estado de São Paulo, Istituto Oncologico Veneto, Institute of Oncology Prof. Dr. Ion Chiricuta, Fondazione IRCCS Istituto Nazionale dei Tumori, Hospital Universitario de Valme, Seoul National University, Seoul National University Hospital, Centre Hospitalier de l’Université de Montréal, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Centre Hospitalier Universitaire de Nantes, Nantes Université, AstraZeneca (Canada), AstraZeneca (United Kingdom), Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,910
OpenAlex ID: W7138190920